Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol for lower limb ischemia-reperfusion–related lung injury in elderly knee arthroplasty
ChiCTR2600130867Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in postoperative respiratory complications (PRC) and lung ischemia-reperfusion injury (IRI) (2 arms), sponsored by The Third Hospital of Hebei Medical University. Primary endpoint: Postoperative pulmonary complications. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
postoperative respiratory complications (PRC)lung ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on ChiCTR2600130867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130867.